323 related articles for article (PubMed ID: 6446379)
21. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
Kleinman R; Dray S
Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
[TBL] [Abstract][Full Text] [Related]
22. Ability of cyclophosphamide in the absence of cross-linking activity to exert the immunomodulatory effect required for the cure of mice bearing a large MOPC-315 tumor.
Mokyr MB; Brundrett RB; Colvin M; Dray S
Cancer Res; 1986 Jul; 46(7):3313-20. PubMed ID: 3486709
[TBL] [Abstract][Full Text] [Related]
23. Imuran-induced regression of plasma cell tumor MOPC-315.
Schlossberg M; Hollander VP
Cancer Res; 1973 Aug; 33(8):1953-6. PubMed ID: 4720804
[No Abstract] [Full Text] [Related]
24. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
Cihak J; Ziegler HW; Kölsch E
Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma.
Hiramoto RN; Ghanta VK
Cancer Res; 1974 Jul; 34(7):1738-42. PubMed ID: 4833918
[No Abstract] [Full Text] [Related]
26. Association of host immunity with 5-fluorouracil-initiated cure of plasmacytoma LPC-1 in BALB/c mice.
Teller MN; Faanes RB
Cancer Res; 1980 Aug; 40(8 Pt 1):2790-5. PubMed ID: 6966969
[No Abstract] [Full Text] [Related]
27. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.
Wise JA; Mokyr MB; Dray S
Cancer Immunol Immunother; 1988; 27(3):191-7. PubMed ID: 3263205
[TBL] [Abstract][Full Text] [Related]
28. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
Cihak J; Ziegler HW; Kölsch E
Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
[TBL] [Abstract][Full Text] [Related]
29. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
30. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
Mokyr MB; Barker E
Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
[TBL] [Abstract][Full Text] [Related]
31. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
32. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
Lubet RA; Carlson DE
J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
[TBL] [Abstract][Full Text] [Related]
33. Growth characteristics of MOPC-315 plasmacytoma and response to anticancer agents.
Valeriote F; Lynch R; Berger NA; White E; Coulter D
J Natl Cancer Inst; 1981 Jun; 66(6):1083-8. PubMed ID: 7017213
[TBL] [Abstract][Full Text] [Related]
34. Effect of polyethylene glycol 6000 on the generation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells cultured in the presence or absence of inactivated stimulator tumor cells.
Przepiorka D; Mokyr MB; Dray S
Cancer Res; 1980 Dec; 40(12):4565-70. PubMed ID: 7438090
[TBL] [Abstract][Full Text] [Related]
35. Immunosuppression in plasmacytoma: induction of suppressor cells.
Chen Y; Hwang LT; Heller P
Clin Exp Immunol; 1982 Jan; 47(1):191-6. PubMed ID: 6212173
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppression in BALB/c mice bearing the plasmacytoma TEPC-183: massive increase in red pulp macrophages induced by the tumour.
Joshua DE; Humphrey JH; Grennan D; Brown G
Immunology; 1980 Jun; 40(2):223-8. PubMed ID: 7409859
[TBL] [Abstract][Full Text] [Related]
37. The mode of action of splenic suppressor cells in murine plasmacytoma.
Chen Y; Heller P
Clin Exp Immunol; 1981 Sep; 45(3):514-22. PubMed ID: 6461449
[TBL] [Abstract][Full Text] [Related]
38. [Effect of the cell dose on the development of 2 transplantable tumors in a syngeneic host].
Pugliese A; Choc O
G Batteriol Virol Immunol; 1976; 69(1-6):122-31. PubMed ID: 15919
[TBL] [Abstract][Full Text] [Related]
39. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
Rubin M; Bluestone JA; Newell KA; Prokhorova A; Mokyr MB
J Immunol; 1994 Apr; 152(7):3522-9. PubMed ID: 8144932
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
Hiramoto R; Ghanta V; Durant JR
Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
